Showing Random 30 of the available attendees
Dr. Robert Sami Nemr
Origin from Rashaya El Wadi, born in Beirut in 1959, I moved to São Paulo- Brazil on july 1976. I studied Medicine in São Paulo University , and Ophthalmologist since 1986, in my private clinic CLONE CLÍNICA OFTALMOLÓGICA NEMER. 20 years ago,
I had been The Chief of Ophthalmology Department of CEMA hospital in São Paulo, during 10 years.
In 1997, a group of Lebanese doctors from Brzil , including me, we founded the AMLB
(Lebanese Brazilian Medical Association) with the proposal to join each other in a strong group for philanthropic work in Brazil and Lebanon, and to strengthen ties between doctors of both coutries in academic and practice works, as well as with all Lebanese Doctors in the World (by ILMA- International Lebanese Medical Association)
Request a Meeting
Dr. Mounir Rahme
JUST TO SAFE TIME, WAIVE COMPLICATIONS AND SOLVE CONFLICTS:
Following several consecutive meetings of Lebanese Diaspora Energy, it seems that the LDE becoming more likely as "the Lebanese Disparate for Energy".
We are still organizing meetings without any clear plan for energy exploitation – except negotiating deals with foreign companies (Russian, Italian, ). However, the full exploitation is already started by other competitive country which could lead to emptying the reserve prior to even starting-up by our government?
In brief, another natural resource from the Lebanese Land will be possible by exploiting the use of the cannabinoid for medical purposes - safer & faster boost to the Lebanese economy…
Please see the following links with proudly remembering leaders/scientists from our heritage who initiated highly leveled projects with no fear whatsoever and from whosoever to promote the Lebanese economy - such as Mr. Camille Chamoun, Mr. Rafik Hariri, Mr. Hassan Kamel el-Sabah, Mr. Kamal Jumblatt,
1- http://entrepreneurs.utoronto.ca/events/2019-04-04/ :
Cannabis Innovation Summit
April 4 @ 8:00 am - 2:30 pm
Cannabis Innovation Summit
Presented by the University of Toronto together with its affiliated hospital partners and the Toronto Cannabis & Cannabinoid Research Consortium (TC3). Part of Health Innovation Week 2019.
Date: Thursday April 4th, 2019
Time: 8:00am – 2:30pm
Location: MaRS Auditorium
101 College Street, Toronto
The use of cannabis for medicinal purposes has opened up a number of questions pertaining to the safety and efficacy for particular disease indications and long term use. This timely summit will discuss the questions that need to be addressed for the health and safety of patients using cannabis to treat disorders, ailments and disease as well as promote the essential evidence-based research that needs to take place in order to address some of these questions.
The summit will also launch the Toronto Cannabis & Cannabinoid Research Consortium (TC3), which brings together cannabis and cannabinoid researchers, scientists, and clinicians from the University of Toronto and its affiliated hospital partners.
The summit will focus on the drug development of cannabis and cannabinoid related therapies and drug delivery mechanisms from discovery to innovation. It will explore various clinical applications and trials around the assessment of the safety and efficacy of cannabis as a medicine and discuss important societal issues as it relates to mental and body health.
This event will also bring together scientists, government officials, policy-makers, research funding organizations, and industry partners who are interested in research and innovation in this field. The goal of the summit is to offer the opportunity to network, seek new collaborations, and share health research findings related to cannabis and cannabinoids. The symposium will feature talks and panel sessions, and will serve as an interactive platform to highlight preclinical, clinical, and public health and policy research in Toronto.
2- https://www.utoronto.ca/news/researchers-u-t-affiliated-hospitals-form-research-consortium-study-risks-and-benefits-cannabis :
The summit heard a range of concerns from researchers about potential harms from cannabis use, including the impact of second-hand smoke, the effects on pregnant women and their fetuses, and altered brain chemistry in young adults and adolescents.
But investigators indicated they were also inspired by the tantalizing hints of potential benefits from cannabis in all its variations.
The list of potential benefits with at least some scientific validation includes chronic pain, epilepsy, MS, depression, anxiety, chemo-related nausea, autism, PTSD, Tourette syndrome and glaucoma, as well as some aspects of Alzheimer’s.
“Cannabis clearly works in epilepsy,” said Mac Burnham, a U of T professor emeritus and co-director of the Epilepsy Research Program at the Ontario Brain Institute.
Burnham wants to focus on treatment ratios between CBD and THC – the principal psychotropic in cannabis – because patients say they work better together. But he had to stop his experiments because of delays in getting a licence from Health Canada.
Scientists at the summit were cautioned to guard against their research becoming tainted by perceived bias or influence, especially by tobacco and alcohol companies that are moving into cannabis.
“We have to be careful to protect our independence,” said Dr. Bernard Le Foll, a professor at the Institute of Medical Science who is also on the TC3 steering committee. But he added that in some cases involving medical cannabis research, there are partnerships with pharmaceutical companies that are “beneficial and appropriate.”
The summit was told the need for research is growing along with the scope of the potential public health aspect. Approximately 10 per cent of Canadians have consumed cannabis in the last year and 40 per cent have used it at some point.
CBD was singled out for the particular concern around the lack of understanding about how it works.
“We really need to know what are the risks associated with its use,” said Dr. Romina Mizrahi, an associate professor in the departments of psychiatry, pharmacology and toxicology and the Institute of Medical Science who focuses on youth mental health and addiction.
“Anecdotally, we have seen an increase of patients with psychosis coming into the clinic using CBD for treatment,” said Mizrahi, a TC3 steering committee member.
About nine per cent of users develop cannabis dependency, but society has to balance those harms against opioids, said Daniele Piomelli of the University of California, Irvine, the keynote speaker at the summit.
“Cannabis can cause acute toxicity but there is no evidence of lethality, even after decades and decades of use.”
He also said research suggests the human body – which has its own endocannabinoid system – could one day be stimulated to enhance such things as energy levels, mood regulation and pain reduction, the same way cannabis seems to.
“We could use our own cannabinoid system to achieve the same effect, and that would be better than administering THC,” said Piomelli.
Marc Mounir Rahme, PhD
Doctor of Pharmacology & Professor, Ottawa University
Request a Meeting